Skip to main content
Premium Trial:

Request an Annual Quote

APBiotech Licenses GFP Technology from Aurora Biosciences

NEW YORK, Sept. 10 – Amersham Pharmacia Biotech has licensed green fluorescent protein technology from Aurora Biosciences, the company announced Monday.

The license gives APBiotech worldwide exclusive rights to the technology, said Kevin McCormack, marketing director for lead screening systems at APBiotech.

The company would not disclose the length of the licensing agreement or financial details of the agreement.

GFP technology aids researchers in identifying cellular expressions of a gene by enabling fluorescent detection of the phenotype. Applications of the technology include functional genomics, high-throughput screening assays, and gene profiling to assess the potential toxicity of compounds.

McCormack said the Aurora license would augment the GFP technology APBiotech already licenses from Denmark-based BioImage, giving customers one-stop access to GFP technology.

“In order to utilize GFP, you need a specific set of mutations, a very complex web of IP,” said McCormack. “Pooling IP from Aurora and BioImage gives a complete portfolio of IP for our customers.”

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.